content-category-listing

Missed the Harrogate MDS Patients & Family Forum? Catch Up Online!

The latest MDS UK Patient and Family Forum took place in Harrogate on Friday 22nd March. It was an invaluable opportunity for those affected by MDS to hear about the latest developments in MDS research and treatment. The meeting was open to MDS patients and their guests, as well as clinical staff. Patients and their families […]

Read full story

content-category-listing

Survey for AML patients to help measure the effects of new drugs for AML

Currently, several new drugs are being tested in clinical trials, aiming at improving the treatment of haematologic malignancies (HM). These trials, however, measure different results – also called treatment response, or outcomes – which makes it difficult to compare and combine all this information. Lars Bullinger (Charité Hospital in Berlin) makes the following observations: “For […]

Read full story

content-category-listing

Are new cancer drugs been developed and recommended to patients?

Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? The Institute of Cancer Research, London, one of the world’s most influential cancer research organisations, has published an in-depth analysis about the discovery and access of innovative cancer drugs. Read the full report Haematological cancers have seen dramatic […]

Read full story

content-category-listing

A New Edition of the MDS Patient Handbook is out!

Being diagnosed with myelodysplastic syndrome (MDS) can be a shock, particularly when you may never have heard of it. MDS UK has now produced a new edition of the MDS patient booklet, created in cooperation with our colleagues from Leukaemia Care and Bloodwise. At MDS UK, we felt there was an urgent need to revise the […]

Read full story

content-category-listing

Vidaza / Azacitidine: Know more about this drug

Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? Vidaza and Azacitidine are the same drug Azacitidine is the official generic and non-proprietary name given to the drug active ingredient while Vidaza is its trade name. The drug is widely available in the UK for the treatment […]

Read full story

content-category-listing

content-category-listing

What is CAR-T cell therapy? Learn how this immunotherapy works in blood cancer

Research FOR Patients -For an informed and empowered opinion- Have you made your clinical paper accessible yet? Cell therapies, sometimes called “living therapies”, are an especially promising and rapidly growing area of cancer research. One approach that’s been pioneered by Memorial Sloan Kettering researchers, led by investigator Michel Sadelain, is called CAR-T cell immunotherapy. This […]

Read full story

content-category-listing

MDS UK is recruiting!

MDS UK Patient Support Group is looking for two new employees, to assist with the running of the charity. We are a small national charity, offering assistance to patients and families who are diagnosed with the rare blood cancer Myelodysplastic Syndromes (MDS). We are based at King’s College Hospital, which is one of the main expert […]

Read full story

content-category-listing

PANTHER: Clinical Trial Open to Recruitment

  1. SUB-TYPE OF MDS:Higher risk MDS, CMML, low blast count AML
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: Azacitidine, Pevonedistat
Read full story

content-category-listing

BRIGHT: Clinical Trial Open to Recruitment

  1. SUB-TYPE OF MDS:Previously untreated higher-risk MDS, AML or CMML
  2. SEVERITY OF MDS: Intermediate, high risk or very high risk MDS as defined by the World Health Organization (WHO) criteria or Revised International Prognostic Scoring System (IPSS-R)
  3. NAME OF DRUG: Glasdegib, Azacitidine
Read full story
Free donations by shopping